ret

(redirected from Receptor tyrosine kinase)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

ret

[ret]
(chemistry)
The reduction or digestion of fibers (usually linen) by enzymes.

RET.

On drawings, abbr. for return.
References in periodicals archive ?
The receptor tyrosine kinase AXL in cancer: biological functions and therapeutic implications.
Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor associated antigen in Iranian patients with acute lymphoblastic leukemia.
Afatinib is a potent irreversible inhibitor of all members of the ERBB family of receptor tyrosine kinases.
High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets.
Craig Venter Institute (Rockville, MD), Ludwig Institute for Cancer Research, and The Johns Hopkins University School of Medicine identified three novel mutations in two receptor tyrosine kinases in glioblastoma tumors using high throughput sequencing.
These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes, including oncogenesis, metastasis, tumor angiogenesis and maintenance of the tumor microenvironment.
is tivantinib, an oral, selective inhibitor of the c-MET receptor tyrosine kinase.
BerGenBio, a Norway-based biopharmaceutical company, has commenced a phase 1 trial of first-in-class AXL receptor tyrosine kinase inhibitor, BGB324, it was reported on Friday.
9 December 2013 - US-based Kolltan Pharmaceuticals Inc, a private company developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs), said Friday it had signed a licence agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies, without disclosing the licence terms.
ArQule's lead product, in Phase 2 and Phase 3 clinical development, is tivantinib, also known as ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase.
DDR2 is a membrane receptor tyrosine kinase involved in cell adhesion, proliferation and migration.
The company added ARQ 197 is an investigational selective inhibitor of the c-Met receptor tyrosine kinase in combination with erlotinib that is currently in Phase 2 and Phase 3 clinical trials and is not yet approved for use.

Full browser ?